BioCentury

1:09 AM GMT, Sep 27, 2012
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Top Story

BIIB's rFIXFc meets Phase III endpoints

Biogen Idec Inc. (NASDAQ:BIIB) and partner Swedish Orphan Biovitrum AB (SSE:SOBI) said rFIXFc as prophylaxis met the primary efficacy and safety endpoints in the Phase III B-LONG trial to treat hemophilia

Read the full 317 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.